Urapidil

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Urapidil
Accession Number
DB12661
Type
Small Molecule
Groups
Investigational
Description

Urapidil has been investigated for the treatment of Hypertension During Pre-Eclampsia.

Structure
Thumb
3D
Similar Structures
Synonyms
Not Available
Categories
UNII
A78GF17HJS
CAS number
34661-75-1
Weight
Average: 387.484
Monoisotopic: 387.227039814
Chemical Formula
C20H29N5O3
InChI Key
ICMGLRUYEQNHPF-UHFFFAOYSA-N
InChI
InChI=1S/C20H29N5O3/c1-22-18(15-19(26)23(2)20(22)27)21-9-6-10-24-11-13-25(14-12-24)16-7-4-5-8-17(16)28-3/h4-5,7-8,15,21H,6,9-14H2,1-3H3
IUPAC Name
6-({3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}amino)-1,3-dimethyl-1,2,3,4-tetrahydropyrimidine-2,4-dione
SMILES
COC1=CC=CC=C1N1CCN(CCCNC2=CC(=O)N(C)C(=O)N2C)CC1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of adverse effects can be increased when Urapidil is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of adverse effects can be increased when Urapidil is combined with (S)-Warfarin.
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid may increase the hypotensive activities of Urapidil.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Urapidil is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Urapidil.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Urapidil.
4-hydroxycoumarinThe risk or severity of adverse effects can be increased when Urapidil is combined with 4-hydroxycoumarin.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Urapidil.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Urapidil is combined with 5-methoxy-N,N-dimethyltryptamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Urapidil.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5639
PubChem Substance
347828865
ChemSpider
5437
ChEBI
32278
ChEMBL
CHEMBL279229
Wikipedia
Urapidil
ATC Codes
C02CA06 — Urapidil

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingTreatmentAortic Dissection Type B / High Blood Pressure (Hypertension)1
3RecruitingTreatmentHigh Blood Pressure (Hypertension) / Preeclampsia1
3Unknown StatusTreatmentHypertension During Pre-Eclampsia1
4RecruitingTreatmentNontraumatic Intracerebral Hemorrhage, Multiple Localized1
Not AvailableCompletedTreatmentCVA (Cerebrovascular Accident) / Intracerebral Hemorrhage / Intracranial Hemorrhages1
Not AvailableRecruitingDiagnosticGeneral Surgery1
Not AvailableRecruitingTreatmentAging / Anaesthesia therapy / Blood Loss,Surgical / Blood Pressures / General Surgery / Postoperative Delirium1
Not AvailableRecruitingTreatmentScheduled Laparoscopic Surgery1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.541 mg/mLALOGPS
logP1.69ALOGPS
logP1.18ChemAxon
logS-2.9ALOGPS
pKa (Strongest Basic)8.11ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area68.36 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity119.37 m3·mol-1ChemAxon
Polarizability43.07 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0439000000-1f066af9035f53bb2d89
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-0900000000-2ccc838e7c2c252cb8ad

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Phenylpiperazines
Alternative Parents
N-arylpiperazines / Aminophenyl ethers / Methoxyanilines / Anisoles / Dialkylarylamines / Methoxybenzenes / Phenoxy compounds / N-alkylpiperazines / Aminopyrimidines and derivatives / Alkyl aryl ethers
show 12 more
Substituents
Phenylpiperazine / N-arylpiperazine / Aminophenyl ether / Methoxyaniline / Tertiary aliphatic/aromatic amine / Phenoxy compound / Anisole / Dialkylarylamine / Aniline or substituted anilines / Phenol ether
show 28 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 17:31 / Updated on November 02, 2018 07:28